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Summary
The power of T cells for cancer treatment has been demonstrated by the
success of co-inhibitory receptor blockade and adoptive T-cell immunother-
apies. These treatments are highly successful for certain cancers, but are
often personalized, expensive and associated with harmful side effects.
Other T-cell-modulating drugs may provide additional means of improving
immune responses to tumours without these disadvantages. Conventional
chemotherapeutic drugs are traditionally used to target cancers directly;
however, it is clear that some also have significant immune-modulating
effects that can be harnessed to target tumours. Cyclophosphamide is one
such drug; used at lower doses than in mainstream chemotherapy, it can
perturb immune homeostasis, tipping the balance towards generation of
anti-tumour T-cell responses and control of cancer growth. This review dis-
cusses its growing reputation as an immune-modulator whose multiple
effects synergize with the microbiota to tip the balance towards tumour
immunity offering widespread benefits as a safe, and relatively inexpensive
component of cancer immunotherapy.
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Introduction
Mustard gas, a poison used during World War I, dam-
aged eyes, skin and lungs causing great suffering and
death to thousands of soldiers. Autopsies performed on
some of the soldiers who died in this way, revealed
shrunken lymph nodes and depleted bone marrow while
the medical records of others revealed low immune cell
numbers in their blood (reviewed in ref. 1). Louis Good-
man and Alfred Gilman, both doctors at Yale University,
hypothesizing that mustard gas destroyed immune cells,
tested its ability to treat a patient with advanced lym-
phoma.1 Far from the horror of the trenches, clear bene-
fits of this toxic substance were observed, signifying the
advent of chemotherapy.1
With these discoveries, mustard gas served as a starting
point to produce similar but less toxic and more effective
anti-cancer agents. One of these was cyclophosphamide
(CY), becoming one of the earliest anti-cancer drugs first
used in the late 1940s. It is now known that CY is metab-
olized in hepatocytes by P450 oxidases to produce its
active forms namely 4-hydroxycyclophosphamide and its
tautomer aldophosphamide.2,3 Once inside a cell, these
undergo spontaneous degradation into acrolein and the
alkylating agent, phosphoramide mustard, resulting in
DNA cross-linking DNA and apoptosis. Currently, CY is
used as a chemotherapy agent for a range of cancers and
as an immunosuppressive drug to treat autoimmune con-
ditions refractory to standard therapies; novel uses of CY
as a cancer immunotherapeutic agent are also being
explored.
CY and tumour immunity
Robert North and colleagues demonstrated the impact of
CY on tumour immunity in the 1980s. Interpretation of
these experiments was linked to the discovery of a ‘sup-
pressor’ T-cell population capable of promoting tumour
growth through dampening down the anti-tumour
immune response. In these experiments, T cells induced
by immunizing mice with fibrosarcoma cells admixed
with killed Corynebacterium parvum, caused tumour
regression when adoptively transferred into tumour-bear-
ing T-cell-deficient mice, but not when adoptively trans-
ferred with T cells recovered from tumour-bearing mice,
consistent with the hypothesis that tumours induce sup-
pressor T-cell activity.4 Administration of 100 mg/kg CY
was subsequently shown to abrogate the suppressive
effect. Importantly, in the absence of T cells, CY alone
had little or no effect on tumour growth, indicating
immune-modulation by CY, consistent with its ability to
ablate suppressor T-cell activity.4,5 Further evidence for
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an important role for CY in immune-modulation was
obtained when the same group investigated the effects of
CY on anti-tumour immunity using a CY-resistant lym-
phoma cell line (L5178Y). Regression of the lymphomas
was observed if CY was co-administered with donor lym-
phocytes obtained from tumour-sensitized animals; the
minimum CY treatment required was 70 mg/kg. These
results indicate that CY can impart an anti-tumour effect
without a direct impact on the tumour itself.5 Many
recent studies using CY, described in detail below, sup-
port the interpretation of these early reports.
CY and regulatory T cells
Many more studies have since confirmed that ‘suppres-
sor’ T cells, subsequently defined as CD4+ CD25hi Foxp3+
regulatory T (Treg) cells are often enriched within
tumour sites where they may inhibit the activity of anti-
tumour T cells and promote tumour progression.6 Several
suppressive mechanisms used by Treg cells have been
reported, all of which may contribute to the immunosup-
pressive tumour microenvironment, allowing the cancer
to progress (reviewed in ref. 7). It follows that strategies
designed to inhibit Treg cell activity should facilitate pro-
ductive anti-tumour immune responses. It is still the case
however, that specifically depleting Treg cells or blocking
their ability to function/accumulate is challenging because
of a paucity of unique, targetable markers (reviewed in
ref. 7). The possibility of using CY to selectively manipu-
late these cells as part of a cancer immunotherapy is
therefore attractive.
Studies exploring the impact of CY on tumours and/or
the immune system have revealed that in humans,
although high doses of CY are needed for effective
chemotherapy (400–1000 mg/m2) and for inducing sys-
temic immunosuppression, immune-modulation requires
much lower doses (< 300 mg/m2 or ~8 mg/kg). In the
case of rodent models, different laboratories using human
equivalent doses of CY (~ 100 mg/kg) consistently report
a decline in Treg cells following treatment of mice and rats
with CY, probably because of enhanced cell death and
decreased homeostatic proliferation.8–13 Hence, alterations
in Treg cell proportions probably reflect both alterations
in cell number and changes in the balance of different
lymphocyte sub-populations induced because of CY. The
extent and kinetics of alterations in lymphocyte popula-
tions following exposure to CY appear to depend on dose
(higher CY doses are more likely to induce lymphopenia)
and other factors influencing immune activation. Detailed
studies examining the effects of CY on Treg cell function
have revealed that Treg cells recovered from CY-treated
animals are more apoptosis-prone and less suppressive
than those from untreated mice; these effects are not long-
lasting because Treg cells appear to regain normal func-
tion within 10 days after administration of CY.8,12,14
Gene expression analyses conducted on blood, bone
marrow and spleen at various time-points after CY
administration have proven informative in shedding light
on why so many immunological changes are induced.
Moschella et al. revealed that exposure to CY results in
up-regulation of gene signatures for cell death, DNA
repair, pro-inflammatory cytokines/chemokines, and T
helper type 1 (Th1)/Th17 responses, among others.15
These changes were most pronounced early after adminis-
tration of CY (1 day later) implying that immune activa-
tion is triggered as a direct consequence of the cytotoxic
effects of CY. There is also evidence that transient deple-
tion of bone marrow cells by CY induces a rebound mye-
lopoiesis, thereby further perturbing immune
homeostasis, potentially affecting myeloid cells as well as
lymphocytes. Indeed, CY administration has been
reported to increase the frequency of myeloid-derived
suppressor cells, which may serve to limit its immune-
potentiating effects.16–18
Why does CY target Treg cells?
It has been suggested that low-dose CY selectively targets
Treg cells due to the relatively low-levels of ATP present
in these cells compared with other lymphocytes.19 This is
due in part to inhibition of microRNA-142-3p by Foxp3,
the consequence of which is increased synthesis of adenyl
cyclase 9, which drives conversion of ATP into cAMP.
Reduced ATP is significant, as one detoxification method
used by cells to remove active phosphoramide mustard
involves the conjugation of phosphoramide mustard to
glutathione, which is itself synthesized via two ATP-
dependent reactions.19–21 Hence, as a consequence of
reduced ATP, Treg cells harbour relatively low levels of
glutathione and as a result fail to efficiently detoxify CY,
whereas addition of glutathione to Treg cells attenuates
their sensitivity.19 Moreover, the importance of micro-
RNA-142-3p has been validated in experiments where
Treg cells transfected with microRNA-142-3P exhibited an
increase in levels of intracellular ATP and resistance to
CY. Conversely, the introduction of a microRNA-142-3P
inhibitor to conventional T cells led to a decrease in ATP
levels and enhanced sensitivity to CY-mediated killing
in vitro. The ectonucleotidases CD39 and CD73, expressed
on the surface of Treg cells, may also play a role since cat-
abolism of extracellular ATP to adenosine may lead to a
decrease in cytosolic ATP by inducing its release. Antago-
nists of CD39 increase ATP levels in human and mouse
Treg cells, also resulting in resistance to CY.22–24
Cyclophosphamide for cancer immunotherapy –
pre-clinical mouse models
Following the studies of Robert North in the 1970s and
1980s, the ability of CY to exert indirect anti-tumour
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effects through its immune-modulating activity have been
demonstrated.9,25 Motoyoshi et al. compared the effect of
low (20 mg/kg) or high (200 mg/kg) doses of CY in
immunocompetent and nude mice bearing hepatocellular
carcinomas (MH129). An anti-tumour effect was seen at
both CY doses in the immunocompetent mice, but was
only observed at a high dose in the immunodeficient
mice, indicating direct tumour cytotoxicity at a high dose
of CY but an indirect immune-modulating effect at the
lower dose.25 The same group also showed that adoptive
transfer of purified Treg cells to CY-treated tumour-bear-
ing mice negates the ability of CY to promote tumour
immunity.
Through these studies, an emerging consensus is that
CY results in a reduction in the proportion (and possibly
function) of Treg cells, with a concomitant increase
within the CD4+ Foxp3 and CD8+ effector T-cell com-
partments. Several reports indicate that the net effect of
this immune perturbation is to drive anti-tumour
immune responses, as evidenced by increased numbers of
tumour-infiltrating effector T cells and/or control of
tumour progression.9–11,13,26 There are also studies indi-
cating that CY treatment results in an increase in produc-
tion of type I interferon, driving maturation of dendritic
cells.27 This effect together with tumour cell death and
consequent antigen release may be crucial for driving
anti-tumour T-cell responses.28 Recent evidence using
mouse models indicates that enhancing tumour immuno-
genicity through chemotherapy (including CY) -induced
cell death is highly effective at improving responses to
checkpoint blockade.29
Although administration of CY alone can significantly
impair tumour growth in mice,30,31 there is also evidence
from mouse models that the ability of CY to promote
anti-tumour immunity is markedly improved by combin-
ing the drug with other chemotherapeutic32,33 or
immunotherapeutic agents. In the case of the latter,
investigators have demonstrated increased immune
responses and better control of tumour growth after com-
bining low-dose CY with recombinant virus vaccines,34
peptide-based vaccines,35 exome-based vaccines,36 whole-
cell vaccines,37,38 dendritic cell vaccines,39–42 Toll-like
receptor agonists,43 DNA vaccines,44 agonist antibodies
specific for the co-stimulatory molecules, e.g. OX-4028
and 4-1BB,45 and anti-PD-1-blocking antibodies.46 More-
over, administration of CY before adoptive T-cell transfer
significantly improves the performance of the transferred
cells.5
The finding that antibiotics compromised the efficacy
of low-dose CY indicated that its ability to confer anti-
tumour immune effects is also dependent on the presence
of certain microbes in the gut. Findings from mouse
models indicate that key players include the Gram-posi-
tive bacteria, Enterococcus hirae and the Gram-negative
bacteria, Barnesiella intestinihominis.47 Although E. hirae
was shown to promote induction of memory Th1
responses and induction of pathogenic Th17 (defined as
Tbet+ RORcT+ IFN-c+ IL-17+) cells in CY-treated
tumour-bearing mice, B. intestinihominis was associated
with a systemic increase in polyfunctional CD4+ and
CD8+ T cells and a tumour-localized increase in numbers
of interferon-c-producing T cells. Significant increases in
cancer-specific T-cell responses are associated with better
control of tumour growth. Why the presence of these
bacteria should alter the type and size of immune
responses induced because of CY treatment is not yet
known. It is interesting, however, that the efficacy of CY
in tumour-bearing mice previously pre-treated with
antibiotics, was partially restored upon oral gavage com-
prising either organism.47 These findings open exciting
new clinical opportunities for combining CY treatment
with pre-conditioning/colonization of the gut with bacte-
ria that maximize the therapeutic potential of
immunomodulatory drugs.
Cyclophosphamide and metastasis – mouse
models
There are opposing reports regarding the effect of CY on
cancer metastasis, with some suggesting the enhancement
of malignancy after CY treatment.48–51 Carmel and Brown
injected cytotoxic chemotherapeutic drugs into mice
1 day before inoculation with large numbers of tumour
cells to assess the effect on tumour take.51 CY appeared
to have the most significant effect on increasing the num-
ber of lung tumour nodules compared with other com-
monly used drugs. Interestingly, there was a sharp
increase in tumour nodules above a CY dose of 100 mg/
kg, with a maximum dose of 200 mg/kg resulting in a
significant increase in number, possibly as a result of an
effect of CY on the lung tissue.51 CY treatment in mice
has also been observed to cause vascular endothelial cell
damage, allowing for an increase in fibrosarcoma cell
adhesion and embedding in the endothelial membrane,
potentially enhancing metastasis.50 Yamauchi et al.49
found that after CY pre-treatment, mouse fibrosarcomas
became less stable, and were able to extravasate and form
metastatic nodules. More recently Park et al.48 showed
that a single dose of 350 mg/kg CY in mice 7 days before
intracardiac injection of luciferase-labelled PC-3 carci-
noma cells resulted in increased metastasis in hind limb
and mandible compared with saline-treated mice, and
fewer metastatic-free mice 6 weeks after tumour chal-
lenge.48
In contrast, Jia and Waxman showed that low-dose
metronomic CY administration could sensitize KM12
colon carcinoma to the anti-tumour and anti-metastatic
effects of thrombospondin-1 and pigment epithelium-
derived factor, although CY itself did not promote tumour
regression.52 These disparate findings demonstrate how
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high doses of CY appear cytotoxic, whereas metronomic
CY administration can be administered for prolonged
periods of time with minimal side effects to maximize the
anti-tumour response.52
Cyclophosphamide for cancer immunotherapy –
clinical studies
Attempts to compare mouse and human trials using CY
can be made by normalizing to body surface area to cal-
culate animal and human equivalent dose. From these
calculations, the doses used in mice and humans to
achieve immune-modulation are comparable. It remains
difficult, however, to extrapolate dosing regimens from
mouse to humans due to differences in serum half-life
(the serum half-life of CY is < 17 min in mice and 65 hr
in humans).53,54 Similarly, comparing different human
studies is also challenging because of the consequences of
different routes of administration and dosing regimens.
Nevertheless, patterns are emerging regarding the impact
of low-dose CY on the human immune system.
Some of the earliest reports to measure CY activity on
Treg cells in humans involved irradiated cancer cell vacci-
nes in patients with metastatic melanoma. A dose of
300 mg/m2 (approximately 811 or 10138 mg/kg in a
mouse) CY was found most effective at decreasing the
putative suppressor T-cell count.55,56 However, incom-
plete understanding of the phenotype and function of
Treg cells limited these studies at this time.
Several groups subsequently used a daily oral low-dose
metronomic regimen of CY, originally as a salvage ther-
apy in end-stage cancer patients, aimed at inhibiting
tumour angiogenesis.57,58 An important study by Ghir-
inghelli et al. determined that using CY in this manner
actually augments anti-tumour immunity in such patients
through selective effects on CD4+ CD25+ Treg cells,
allowing for greater tumour control.59 A number of
studies have since used similar metronomic dosing regi-
mens to limit Treg cell function to unmask tumour-speci-
fic T-cell responses.60,61 The dose of CY appears crucial
to its immune-potentiating effects as demonstrated in a
clinical trial involving 28 patients with metastatic breast
cancer: HER2-specific antibody responses were enhanced
following vaccination with a granulocyte–macrophage col-
ony-stimulating factor-secreting breast tumour vaccine
and CY administered at a dose < 200 mg/m2 but higher
dosages of CY suppressed these responses.62 With oral
administration, 100 mg given twice-a-day depleted all
lymphocyte sub-populations, whereas 50 mg twice-a-day
was selective for Treg cells.59 These studies serve to high-
light the narrow therapeutic window of CY on anti-
tumour immune responses, corresponding with data col-
lected using mouse models.
Several clinical trials using CY have been conducted.
Greten et al.63 assessed the effect of an intravenously
administered dose of 300 mg/m2 CY in conjunction with
a telomerase peptide vaccine in hepatocellular carcinoma
patients, but no definitive conclusions as to its efficacy
could be drawn. However, an identical dose before treat-
ment with a renal cell cancer vaccine (IMA901) had a sig-
nificant and prolonged effect on Treg cell proliferation,
reducing their overall number.64 In addition, a trend for
prolonged survival was seen in CY-treated patients, being
one of the first randomized trials to demonstrate a bene-
ficial effect of single-dose CY at improving the clinical
efficacy of a vaccine. A beneficial effect was not observed,
however, in a phase III trial, although the results of this
are confounded by addition of sunitinib as part of the
drug combination, which has other, possibly conflicting,
immune-modulating effects.65
Some groups have also failed to observe sufficient
depletion of Treg cells using iterative dosing regimens in
patients with metastatic melanoma.66–68 In spite of these,
improved anti-tumour immune responses were
Measurements of efficacy to include:
Proliferation analysis (%Ki67)
Repeat measurements
i.v. CY (300 mg/kg)
p.o. CY (50 mg b.d.) p.o. CY (50 mg b.d.)











- Tumour-specific IFN-γ T-cell responses
Figure 1. Proposal for measuring the immune-modulating effects of cyclophosphamide (CY). Future studies of the effects of CY should incorpo-
rate baseline measurements and aim to perform analyses of immune cell subsets at many time-points post-administration. Such analyses should
take into account numbers, proportions and function of immune cell subsets as well as cancer-specific T-cell responses. Measuring the impact on
intestinal permeability and microbial translocation should also be considered. p.o. per oral, i.v. intravenous.
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reported.66 A study of 300 mg/m2 CY in ovarian cancer
found neither a quantitative reduction nor qualitative dif-
ference in CD4+ Foxp3+ Treg cell function.69 Despite this,
patients receiving CY had enhanced vaccine-induced anti-
tumour Th1 effector responses, so displaying differential
effects on potentiating vaccine immunogenicity. It is pos-
sible that the transient nature of the effect of CY on Treg
cell numbers and frequencies precludes detection of the
effect while the consequential increase in anti-tumour
effector T-cell responses may be longer-lasting.
Again, these results contrast with another study using
300 mg/m2 CY in melanoma patients, which reported
small, transient depletions of Treg cells.70 The differential
effect could be due to the use of CY in patients with
earlier stage cancers and hence lower tumour burdens;
baseline frequencies of Treg cells in this patient group,
although greater than healthy controls, was statistically
lower than in patients with late-stage melanoma,70 a
finding also observed in colorectal cancer.61 A recent
randomized controlled phase I/II study performed by
our group administered low-dose CY with or without a
modified vaccinia Ankara-based vaccine encoding the
oncofetal antigen 5T4 (TroVax) to stage IV colorectal
cancer patients,71,72 a notoriously poorly responsive
tumour to immunotherapy.73 Compared with no treat-
ment control patients, Treg cell depletion was observed
in 24/27 (89%) patients receiving 50 mg CY twice a day,
although unlike previous reports, significant B-cell and
natural killer cell depletion was also detected. Notably,
significant increases in the frequency and magnitude of
5T4-specific interferon-c+ and granzyme B+ T-cell
responses were observed, but not for control antigens;
these were associated with a significant increase in pro-
gression-free survival.71,72 Unexpectedly, although Tro-
Vax also induced beneficial anti-5T4 cellular and
humoral responses to the benefit of patient progression-
free and overall survival, there was no synergistic effect
of combining CY with vaccine in terms of boosting
observed anti-5T4 immunological responses or patient
survival.71 This warrants further, larger-scale trials of CY
and vaccination strategies in colorectal cancer, possibly
with different treatment timings.
Overall, the information yielded so far regarding the
impact of low-dose CY on the human immune system is
incomplete and argues for more comprehensive analyses
of Treg cells in future trials. It is abundantly clear from
this review that comparing studies is difficult as even
when studies use the same dosage and route of adminis-
tration, Treg cells are often analysed using different meth-
ods at different time-points. This may explain why some
investigators report significant effects on Treg cells
whereas others do not. Indeed, in the case of the trial
described above, the impact of CY on Treg cells was dis-
covered due to the increased number of time-points at
which the cells were analysed. It is worth noting that had
Treg cells been assessed just at the start and the end of
the CY course, its effects would have been missed
(Fig. 1).
Conclusion
It is apparent that the dosage and method/frequency of
administration are important factors determining the
immune-modulating effects of CY. Whether a given study
observes depletion of Treg cells may simply depend on
when measurements are made because the impact of CY
on Treg cells is transient. It is probable that low-dose CY
only targets certain Treg cell sub-populations that are
actively dividing in vivo.26,72
Most published data have demonstrated a beneficial
effect of CY (in doses as low as 50 mg/day) in amplifying
the immune response against tumours. Future trials are
likely to incorporate other immune-modifying treatments
to enhance the efficacy of CY, for example in combina-
tion with novel ‘oncomicrobiotics’, or to maximize the
impact of CY on potentiating anti-tumour immune
responses with co-inhibitory receptor blockade. It remains
important to define mechanisms through which these
immune interventions work; CY does not always potenti-
ate vaccine immunogenicity and studies in mice and
humans imply that dosing regimens can influence the
effect of CY and the efficacy of different combination
approaches.74 In a climate where novel immunotherapies
are being rapidly produced and where testing combina-
tion immunotherapies is extremely attractive, making
informed choices is important. CY is an economically
attractive drug and a careful reassessment of its mecha-
nisms of action may point to a prominent role for CY in
future cancer immunotherapies.
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